Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Engage Grants Program

Dalhousie University

$25,000.00

Developing Resorbable and Drug-Eluting Embolization Microspheres

EF 2016-17

Résumé
ABK Biomedical is a medical device company specializing in materials that can be injected into blood vesselsin order to block blood flow to a target tissue (a process called embolization). ABK's embolization materialsare intrinsically radiopaque, meaning that physicians can monitor their placement using conventional imagingtechniques, but they do not break down in the body. The company would like to expand its product line toinclude radiopaque embolization materials that will eventually break down (resorb) and be assimilated by thesurrounding tissues while slowly releasing drug into this localized region.Phosphate-based glasses developed by the Filiaggi group at Dalhousie University have the advantage of beingresorbable and can, under highly controlled low-temperature processing conditions, be loaded with drugs thatcan be released as the glass resorbs. Recent studies have further demonstrated that these processing conditionscan be adapted to produce small glass spheres or beads.In this project we will develop radiopaque embolic microspheres that resorb within 1 to 3 weeks and can beloaded with - and subsequently release - the most commonly used embolization drugs. To achieve these goals,we will systematically modify the composition of the phosphate glass and evaluate the degradation,radiopacity, and drug loading efficiency and release in order to determine the processing conditions (andresulting formulations) best suited to meet the medical device design requirements. With assistance from ourindustrial partner we will also assess the ease with which these beads can be delivered in a catheter - theprimary mode of delivery for embolization procedures, and employ design methods to enhance microsphereproduction efficiency in the 100-300 µm size range, as is desired for embolic applications.With funding from this NSERC Engage grant, a new and ongoing industry collaboration will be forged thatwill yield novel resorbable, radiopaque and drug-eluting embolization materials of considerable commercialinterest.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Nova Scotia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
492538-2015
Name nom
Filiaggi, Mark
Department département
Applied Oral Sciences,
Organization id
79
Institution établissement
Dalhousie University
Province en
Nova Scotia
Province fr
Nouvelle-Écosse
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2015
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1551
Committee name en
Atlantic Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Atlantique
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1902
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical materials
Research subject fr
Matériaux biomédicaux
Partie
1
Nb partie
1
Application title
Developing Resorbable and Drug-Eluting Embolization Microspheres
Keyword
NSERC
Application summary
ABK Biomedical is a medical device company specializing in materials that can be injected into blood vesselsin order to block blood flow to a target tissue (a process called embolization). ABK's embolization materialsare intrinsically radiopaque, meaning that physicians can monitor their placement using conventional imagingtechniques, but they do not break down in the body. The company would like to expand its product line toinclude radiopaque embolization materials that will eventually break down (resorb) and be assimilated by thesurrounding tissues while slowly releasing drug into this localized region.Phosphate-based glasses developed by the Filiaggi group at Dalhousie University have the advantage of beingresorbable and can, under highly controlled low-temperature processing conditions, be loaded with drugs thatcan be released as the glass resorbs. Recent studies have further demonstrated that these processing conditionscan be adapted to produce small glass spheres or beads.In this project we will develop radiopaque embolic microspheres that resorb within 1 to 3 weeks and can beloaded with - and subsequently release - the most commonly used embolization drugs. To achieve these goals,we will systematically modify the composition of the phosphate glass and evaluate the degradation,radiopacity, and drug loading efficiency and release in order to determine the processing conditions (andresulting formulations) best suited to meet the medical device design requirements. With assistance from ourindustrial partner we will also assess the ease with which these beads can be delivered in a catheter - theprimary mode of delivery for embolization procedures, and employ design methods to enhance microsphereproduction efficiency in the 100-300 µm size range, as is desired for embolic applications.With funding from this NSERC Engage grant, a new and ongoing industry collaboration will be forged thatwill yield novel resorbable, radiopaque and drug-eluting embolization materials of considerable commercialinterest.